The Effect of E-Health Management on Gestational Diabetes Control
Randomized Controlled Trail of e-Health Management for Women With Prior Gestational Diabetes Mellitus
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Background: Women with previous gestational diabetes mellitus are at increased risk for developing type2 diabetes mellitus or metabolic syndrome in their later life. Infants of mothers with GDM are more susceptible to stillbirth and more serious health concerns. With limited time for visits and the predicament of education, applying web-based intervention has become a convenient tool for health management.
Objectives: The approved project aimed to develop an e-heath management platform(eHMP) for women with high risk of gestational diabetes mellitus (GDM) and to evaluate the longitudinal effects between groups of eHMP intervention. The eHMP integrate GDM health care knowledge, self-awareness of health, self-monitoring of health status (i.e., recording weight and measurement data of metabolic syndrome risk factors and monitoring changes in data trends); participation in discussions or browsing forums; healthy lifestyle guidance and counseling; reminder systems, a token system of earning points in exchange for prizes.
Methods: Pregnant women aged 18-45 years with high risk of metabolic syndrome who have a singleton pregnancy, are eligible to participate in this study. Women who agree to participate in the study will be given a participant information sheet and consent form. Participants will be recruited from the Pregnancy diabetes Clinic, at Chang Gung memorial hospital and introduced to the eHMP using the mobile phone in the clinic. Participants will also be given the URL to access to the program and they can learn the modules at home by using their home PCs, mobile phones, or tablets. They were followed up for three times: 28 weeks' gestation, 36-40 weeks' gestation and 6-12 weeks postpartum. SPSS version 20.0 software was used to compile and analyze the research data, including questionnaires and blood test for metabolic index.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Taipei, Taiwan, 10507
- Chang Gung Memorail Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Pregnant women (pre-pregnancy body mass index ≧ 24) must meet at least one of the following conditions and agree to be interviewed:
- Age over 34 years old;
- Ever had giant infant delivery (weight ≧ 4.5 kg);
- Previous diagnosed with gestational diabetes ;
- Family history of diabetes.
Exclusion Criteria:
- Pre-existing diabetes (types 1 and 2);
- Unable to write and understand Chinese;
- Subject has cognitive impairment;
- Subject has intellectual disability or mental illness;
- Dependent on medical care (eg, anti-depressants, or any psychiatric medication)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: eHMP experimental group
The experimental group received health management support and counseling,including:
|
Pregnant women who agree to take part will be assigned to a group: experimental group and control group.
The experimental group will received health management support and counseling that were conducted by the researchers through the e-health management platform.
Andre navne:
|
|
Ingen indgriben: Control group
only received usual care
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change of Triglyceride Level
Tidsramme: Change from Baseline at 6-12 weeks after delivery
|
Blood sampling was performed in the fasting state.
Normal triglyceride was <150 mg/dl; ≥150mg/dl was abnormal
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of Fasting Blood Glucose (FBG) Level
Tidsramme: Change from Baseline at 6-12 weeks after delivery
|
Blood sampling was performed in the fasting state.
Normal FBG was < 100 mg/dl; ≥100mg/dl was abnormal
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of high-density lipoprotein cholesterol (HDL) level
Tidsramme: Change from Baseline at 6-12 weeks after delivery
|
Blood sampling was performed in the fasting state.
Normal HDL was ≥50 mg/dl; <50mg/dl was abnormal
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of Cholesterol level
Tidsramme: Change from Baseline at 6-12 weeks after delivery
|
Blood sampling was performed in the fasting state.
Normal Cholesterol was < 200 mg/dl; ≥200mg/dl was abnormal
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of systolic blood pressure
Tidsramme: Change from Baseline at 6-12 weeks after delivery
|
Normal systolic blood pressure was <130mmHg; ≥130mmHg was abnormal.
Blood pressure was measured at the right arm twice after a 10-min rest in the supine position by using a calibrated sphygmomanometer and averaged.
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of diastolic blood pressure
Tidsramme: Change from Baseline at 6-12 weeks after delivery
|
Normal diastolic blood pressure was <85mmHg; ≥85mmHg was abnormal.
Blood pressure was measured at the right arm twice after a 10-min rest in the supine position by using a calibrated sphygmomanometer and averaged.
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of body weight
Tidsramme: Change from Baseline at 6-12 weeks after delivery
|
Women's weight following as assessed using calibrated digital scales
|
Change from Baseline at 6-12 weeks after delivery
|
|
Newborn baby weight
Tidsramme: at birth
|
Newborn baby weight in normal range (>2500g - <4500g) - dichotomous outcome Yes/No assessed using calibrated digital scales.
|
at birth
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change of Pregnancy Physical Activity Assessment
Tidsramme: Change from Baseline at 6-12 weeks after delivery
|
There are 12 items in this questionnaire, including two dimensions: exercise and inactivity.
Exercise dimension contained four items to assess the type of physical activity, intensity, duration, frequency during pregnancy.
At least 3 days per week, and each time at least 20-30 minutes, counted as regular exercise (dichotomous outcome Yes/No assessed).
Inactivity dimension contained 8 items, dichotomous outcome Yes/No assessed (score 0-8), higher values represent an inactivity lifestyle.
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of Dietary Behavioral Characteristics Scale
Tidsramme: Change from Baseline at 6-12 weeks after delivery
|
The instrument is 17-item Likert-type self-report instrument, used a 5-point response format to obtain data regarding the frequency of reported behaviors (never, rarely, sometimes, usually, always).
It including two dimensions and each scale range as: balanced diet (5 items, scale range 5-25) and diet control behavior (12 items, scale range 12-60).
Higher values represent a better maternal dietary patterns during pregnancy.
|
Change from Baseline at 6-12 weeks after delivery
|
|
Change of Health Promotion Scale
Tidsramme: Change from Baseline at 6-12 weeks after delivery
|
The instrument is 40-item Likert-type self-report instrument, used a 5-point response format to obtain data regarding the frequency of reported behaviors (never, rarely, sometimes, usually, always).
It including six dimensions and each scale range as: social-support (6 items, scale range 6-30), life-appreciation (8 items, scale range 8-40), health-responsibility (8 items, scale range 8-40), stress-management (9 items, scale range 9-45), nutritional behaviors (5 items, scale range 5-25) and exercise behaviors (4 items, scale range 4-20).
The total score was 40 to 200, higher values represent a better health promotion lifestyle.
|
Change from Baseline at 6-12 weeks after delivery
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Mei-Chen Su, Dr., Chang Gung Memorial Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 105-4129C
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .